These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1343799)

  • 21. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection.
    Jones DE; Buxbaum LU; Scott P
    J Immunol; 2000 Jul; 165(1):364-72. PubMed ID: 10861073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leishmania amazonensis: humoral response to amastigote excreted-antigens in murine leishmaniasis.
    Hernández-Chinea C
    Exp Parasitol; 2007 Aug; 116(4):492-6. PubMed ID: 17349625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response.
    Alexander J; Coombs GH; Mottram JC
    J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of anti-leishmanial effects of killed Leishmania vaccine with BCG adjuvant in BALB/c mice infected with Leishmania major MRHO/IR/75/ER.
    Nahrevanian H; Jafary SP; Nemati S; Farahmand M; Omidinia E
    Folia Parasitol (Praha); 2013 Feb; 60(1):1-6. PubMed ID: 23539946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological correlates of cure in the first American cutaneous leishmaniasis patient treated by immunotherapy in Argentina. A case report.
    García Bustos MF; Barrio AB; Parodi Ramoneda CM; Ramos F; Mora MC; Convit J; Basombrío MA
    Invest Clin; 2011 Dec; 52(4):365-75. PubMed ID: 22523846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.
    Leal JM; Mosquini M; Covre LP; Stagmiller NP; Rodrigues RR; Christensen D; de Matos Guedes HL; Rossi-Bergmann B; Gomes DC
    Parasitology; 2015 Nov; 142(13):1640-6. PubMed ID: 26394776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathologic changes induced by vaccination in experimental cutaneous leishmaniasis of BALB/c mice.
    Barral-Netto M; de Freitas LA; Andrade ZA
    Am J Pathol; 1987 May; 127(2):271-8. PubMed ID: 3495185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.
    Mahmoodi M; Khamesipour A; Dowlati Y; Rafati S; Momeni AZ; Emamjomeh M; Hejazi H; Modabber F
    Clin Exp Immunol; 2003 Nov; 134(2):303-8. PubMed ID: 14616791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Determination of the specificity of seric IgA produced in response to antigens of Leishmania (Leishmania) mexicana in murine leishmaniasis].
    Pérez-Aguilar MC; Hernández O; Maizo de Segnini Z; Rojas CH; Díaz S; Alarcón M; Goncalves L
    Invest Clin; 2011 Sep; 52(3):216-29. PubMed ID: 21950193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan.
    Pinheiro RO; Pinto EF; de Matos Guedes HL; Filho OA; de Mattos KA; Saraiva EM; de Mendonça SC; Rossi-Bergmann B
    Vaccine; 2007 Mar; 25(14):2716-22. PubMed ID: 16814903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
    Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis.
    Michel MY; Fathy FM; Hegazy EH; Hussein ED; Eissa MM; Said DE
    J Egypt Soc Parasitol; 2006 Apr; 36(1):159-76, following 76. PubMed ID: 16605109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
    Sharifi I; FeKri AR; Aflatonian MR; Khamesipour A; Nadim A; Mousavi MR; Momeni AZ; Dowlati Y; Godal T; Zicker F; Smith PG; Modabber F
    Lancet; 1998 May; 351(9115):1540-3. PubMed ID: 10326536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis.
    Padigel UM; Alexander J; Farrell JP
    J Immunol; 2003 Oct; 171(7):3705-10. PubMed ID: 14500669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-beta-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens.
    Pinheiro RO; Pinto EF; Lopes JR; Guedes HL; Fentanes RF; Rossi-Bergmann B
    Microbes Infect; 2005 Oct; 7(13):1317-23. PubMed ID: 16027022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.